Meteoric Biopharma to invest Rs. 25 Cr to set up R&D facility in Hyderabad

Hyderabad: Ahmedabad-based Meteoric Biopharmaceuticals, a first-generation, research-driven, integrated and diversified global biopharma leader, on Tuesday announced to set up its R & D and Innovation facility in Hyderabad with an investment of Rs 25 crore.
With over 100 products, the Company excels in manufacturing and marketing enzymes and enzymatic preparations, probiotics, nutraceuticals, finished formulations and animal healthcare products, said Mr. Gaurav Kaushik, Managing Director and CEO, Meteoric Biopharmaceuticals at a press conference here.
We have two R & D facilities and one state of the art unit at Ahmedabad besides overseas offices in the USA and Vietnam, he said that the proposed R and D and Innovation facility would come up in Hyderabad by the end of this year after shifting one R&D centre from Ahmedabad.
We will also recruit 25 freshers for the Hyderabad facility, Kaushik said that we are spending 15 percent of our revenue on R & D and it would be scaled up in the coming years.
The company’s revenue is expected to touch Rs 200 crore this year against Rs 130 crore last year, he said, adding that the company has 10 patents and over 50 trade marks in its name.
A B2B company, Meteoric Biopharma also offers product customization, concept-based formulation and contract manufacturing under one roof, the CEO said the company has chalked out aggressive growth plans and is working continuously towards introducing novel, cost-effective ingredients and formulations in the biopharmaceutical space through innovative research.
The company also plans to launch more concept-based finished nutraceuticals products, he informed.
“Our future plans include launching Synbiotics (combinations of Pre and Probiotics), expanding our Probiotics & Enzymes production capacity, introducing a unique formulation for Down Syndrome and further expanding exports, Kaushik said innovation and reinventing will drive our biopharma expectation and plan for years to come.
Apart from biopharmaceuticals, we are targeting more industries in the field of bio-agriculture, biosimilars, crop science, and bioenergy in the upcoming years, he added.
Speaking on the industry and expectations from the upcoming budget, Gaurav opined, “India is on the cusp of a massive leap towards being the global biopharma leader. The industry has grown consistently both in terms of production as well as innovation.
As an industry, we are hopeful for a positive Union Budget to integrate public-private partnerships, provide an incentive for R&D, and smoothen supply chain, freight cost and logistics challenges.”
“Indian biopharma companies must ramp up new product and technology capabilities for the next phase of expansion. As learnt from the pandemic, de-risking supply chains, and manufacturing operations while expanding capacity in sensitive APIs and intermediates is critical” he added.